SillaJen and Transgene commence enrolment in Europe for Phase III trial of Pexa-Vec

South Korean-based biotherapeutics firm SillaJen and French biotechnology firm Transgene have commenced patient enrolment in Europe for the ongoing Phase III PHOCUS clinical trial of Pexa-Vec to treat advanced liver cancer or hepatocellular carcinoma …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news